comparative study inhaled atropine sulfate isoproterenol hydrochloride cystic fibrosis investigate contribution vagal tone obstructive airway disease cystic fibrosis evaluated pulmonary function response administration 01 mg atropine sulfate per kg body weight 005 mg isoproterenol hydrochloride per kg body weight isotonic saline control solution administered nebulization 3 different day 10 patient cystic fibrosis single blind study dos atropine sulfate isoproterenol hydrochloride based published doseresponse characteristic drug day thoracic gas volume airway resistance measured volume displacement body plethysmograph maximal expiratory flowvolume curve performed 15 30 60 min inhalation inhalation saline group mean value pulmonary function indicated greater airway obstruction 15 30 60 min compared pretreatment value inhalation isoproterenol atropine significant improvement p 005 noted maximal expiratory flow 60 per cent total lung capacity specific airway conductance thoracic gas volume residual volume inhalation atropine also significantly improved maximal expiratory flow 25 per cent vital capacity isoproterenol increased mean flow 8 46 per cent baseline decreased thoracic gas volume residual volume 11 16 per cent maximal response 15 30 min atropine increased mean flow 15 77 per cent decreased thoracic gas volume residual volume 16 25 per cent maximal effect 30 60 min mean response atropine expressed percentage baseline always greater equal isoproterenol conclude vagal tone may reflect increased irritant receptor activity contributes obstructive pulmonary function cystic fibrosis inhalation atropine sulfate decrease pulmonary function abnormality side effect prohibit clinical usefulness